Trials / Not Yet Recruiting
Not Yet RecruitingNCT07493265
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2086 | E2086 oral tablets. |
| DRUG | Placebo | E2086 matching placebo tablet. |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2027-02-14
- Completion
- 2027-03-01
- First posted
- 2026-03-25
- Last updated
- 2026-03-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07493265. Inclusion in this directory is not an endorsement.